Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0699790 (colon cancer)
 28,837 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In summary, of the 460 patients of primary carcinoma of the liver admitted to the University Surgical Unit at the Queen Mary Hospital over a period of 12 years, more than 40% could not be treated, and only 91 of the patients were candidates for curative resection. The cure rate is very small; a 1- to 2-year survival was obtained in 46% of 15 resections. From 1964 to 1969, out of 22 patients with resections, 3 are still alive more than 5 year after the operation. Lin30 reported a 19.1% 5-year survival. When the hepatoma has ruptured and bleeding takes place, surgical treatment is obligatory to control the hemorrhage. Ninety-eight patients underwent a clinical trial of 5 categories: hepatic dearterialization, hepatic arterial cannulation and infusion of 5-FU, hepatic arterial ligation and portal venous infusion of 5-FU, radiotherapy and no treatment. The results show that the advantage of each form of treatment when compared with no treatment is marginal. Thus a gloomy picture of primary hepatoma is held. Since the operative mortality of hepatic resection for a solitary secondary carcinoma of the liver is negligible, it should be done in each instance because a long-term survival may be possible. This is especially true with primary carcinoma of the colon.
 ...
PMID:Techniques and therapies for primary and metastatic liver cancer. 8 19

The fact that the national death rate from carcinoma of the colon and rectum has remained static over the past two decades is strong incentive for future investigation of measures to allow detection in its early and more favorable stage. Although no significant improvements in surgical techniques have afforded improvement in longevity, certain technical factors are known to inhibit tumor implantation during surgery. Data suggest that the extent of en bloc resection is the most crucial factor in avoiding recurrence. Extensive use of radiotherapy as the sole method of treatment or as preoperative or postoperative adjunctive therapy remains investigational, but it seems likely that this form of treatment will play an increasing role in the future. Preoperative radiotherapy seems to be useful in reducing the stage of the neoplasm and the incidence of extraserosal involvement; postoperative radiotherapy is beneficial for palliation. Chemotherapy, particularly with the fluorinated pyrimidines (5-FU and 5-FUDR), is being evaluated for its usefulness in lengthening survival time; response to 5-FU is occasionally dramatic. It remains for major investigational centers to clarify the role of combination chemotherapy in metastatic disease. Immunotherapy at present must be considered an unproven mode of treatment and of inconclusive benefit in any stage of colorectal carcinoma. Carcinoembryonic antigen assay is a useful prognostic and diagnostic tool in localizing primary tumor and in subsequent evaluation of response to treatment.
 ...
PMID:Colorectal carcinoma: overview of management techniques. 15 80

An in vivo model is described for assessing the antitumor activity of chemotherapeutic agents. Tumors derived from human colon carcinoma cell lines injected into antithymocyte serum (ATS) immunosuppressed mice were used. In this system, both antitumor effects and host toxicity can be quantitated, permitting calculation of a Therapeutic Index. Compared with other xenograft models, the present system is simple, experiments are completed in less than 2 weeks, and the use of cultured cell lines allows in vitro studies to be performed. The in vitro sensitivities of one colon cell line to 22 chemotherapeutic agents and of four cell lines to three agents is reported. Four drugs used in treating colon cancer (Mitomycin C, 5-FU, BCNU, and methyl-CCNU) show antitumor activity in vivo in this system. Each has a low therapeutic index. Further work with this model is indicated, with the goal of finding new drugs with high Therapeutic Indices.
 ...
PMID:Chemotherapy of cell-line-derived human colon carcinomas in mice immunosuppressed with antithymocyte serum. 30 40

In order to determine the minimal toxic dose of a 5-day infusion of 5-fluorouracil (5--FU) in combination with an infusion of thymidine (TdR), 12 patients, received TdR at a dose of 8 g/m2/day for 5 1/2 days, beginning at the same time as a 5-day infusion of 5-FU at doses of 5--20 mg/kg/day. Myelosuppression was the dose-limiting toxicity, and the minimal toxic dose of 5--FU was found to be 7.5 mg/kg/day. Gastrointestinal toxicity was minimal to absent. In eight patients with carcinoma of the colon who had received no prior chemotherapy, there were two patients with partial responses (at doses of 5.0 and 7.5 mg/kg/day of 5--FU), two patients with stable disease, one patient with progressive disease, and three patients with early death (two drug-related deaths and one disease-related death). In four patients who had received prior 5--FU, one had stable disease, one had progressive disease, and two had early death (one drug-related death). We conclude that the addition of TdR to 5--FU infusions changes the dose-limiting toxicity from gastrointestinal toxicity to myelosuppression. The minimal toxic dose is decreased to approximately one third of that when 5--FU is administered alone.
 ...
PMID:Phase I study of thymidine plus 5-fluorouracil infusions in advanced colorectal carcinoma. 36 80

The therapeutics on gastrointestinal cancer including only randomized clinical trials carried out in Western Europe and in the EORTC are reported. The studies on preoperative radiotherapy in resectable esophagus cancer and on chemotherapy associated to radiotherapy in nonresectable esophagus cancer has just been activated. The data of a trial on the treatment of gastric cancer have demonstrated the efficacy of long term 5-FU administered after postoperative irradiations. A trial on the immunostimulating effect of levamisole as adjuvant treatment of colon cancer is described, as well as the results of chemotherapy in advanced colon cancer. Finally, scribed, as well as the results of chemotherapy in advanced colon cancer. Finally, the preliminary results of two European trials studying the effect of preoperative radiotherapy and of a chemotherapy, used as a preoperative irradiation sensitizer in rectal cancer, are commented on.
 ...
PMID:Clinical trials on gastrointestinal cancer in Western Europe and in the FORTC. 65 75

This study compares the effectiveness of hepatic arterial infusion of mitomycin C with that of 5-fluorouracil in the management of carcinoma of the colon metastatic to the liver. A higher tumor response rate was obtained with 5-FU (ten of 12 patients) than with mitomycin C (six of 13 patients). The patients treated with mitomycin C had a median survival time of 9.5 months compared to 12 months for those receiving 5-FU, but this survival is not much different from that of the untreated historical controls. Femoral artery thrombosis requiring surgical thrombectomy developed in five of the 30 catheterized patients.
 ...
PMID:Hepatic arterial infusion for liver metastases from colon cancer: comparison of mitomycin C(NSC-26980) and 5-fluorouracil (NSC-19893). 109 98

Antitumor polyoxomolybdates have been recognized in the course of study on the medical utilization of polyoxometalates, inorganic polymers of metal oxide. [NH3Pri]6[Mo7O24].3H2O (PM-8) was found as a representative of antitumor polyoxomolybdates. The growth suppressions of PM-8 against Co-4 human colon cancer xenografted under the subrenal capsule in cd-1 mice were equal or superior to that of 5-FU, MMC, ACNU, ADM and CDDP. Potent antitumor activity of PM-8 is also established against MX-1 human breast and OAT human lung cancer xenografted in athymic nude mice. Polyoxomolybdate is a new type of antitumor substance.
 ...
PMID:Antitumor activity of new antitumor substance, polyoxomolybdate, against several human cancers in athymic nude mice. 130 30

Five studies presented at the 1992 ASCO meeting are analysed. Kligerman's study was designed to determine if pre-treatment with WR-2721 could protect normal tissues from the toxicities induced by radiation therapy (in 100 patients with advanced rectal cancer). This pre-treatment resulted in a 13% reduction of moderate and severe acute toxicity. No WR-2721 patient experienced moderate or severe late toxicities compared to five in the group without pre-treatment. The complete response rate was higher in the WR-2721 group and there was no major WR-2721 related toxicity. Minski studied the acute toxicity (during treatment and two weeks after) of combined pelvic radiation therapy, 5-FU and leucovorin when delivered pre-operatively (16 patients) versus post-operatively (25 patients) in patients with rectal cancer. The toxicity criteria were fatigue, diarrhea, tenesmus, bowel movements, dysuria and erythema. Grade 3+ toxicity was more important in the post-operative therapy group (48% versus 13%). Given this high incidence of grade 3+ toxicity future randomized trials should explore the pre-operative approach. The final report of the inter group study of 5-FU plus levamisole as adjuvant therapy for stage C colon cancer was made by Moertel. With a median follow-up time of 5.5 years, the 5-FU plus levamisole treatment has reduced the recurrence rate by 39%, the cancer related death rate by 32% and the overall death rate by 31%. Most of the recurrences occurred during the first two years. There was a decrease in the liver, great omentum, peritoneum and lung metastases, but there was no modification in loco-regional recurrence rate.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Cancers of the colon and the rectum: news in 1992]. 133 19

Intraperitoneal chemotherapy with CDDP and other agents was instituted to treat 2 cases of metastatic ovarian cancer (developing in one case of gastric cancer and one of colon cancer). At first laparotomy, cytological examination of ascites revealed malignant cells in the 2 cases, and metastatic foci were noted in non-ovarian regions as well. Macroscopic peritoneal dissemination was apparent in the case of colon cancer. Following surgery, 5 courses of chemotherapy were given. The gastric cancer patient was treated with intraperitoneal CDDP and etoposide, while the colon cancer patient was placed on intraperitoneal CDDP therapy and continuous 5-FU iv. Clinical CR was 7 months in the former case and 10 in the latter. Although small metastatic foci were present in the posterior peritoneum in both cases at second laparotomy, distinct peritoneal dissemination had disappeared in the case of colon cancer. Cytologic examination of intraperitoneal washings proved to be negative for malignant cells in the gastric cancer case but positive in the colon cancer case. These findings indicated that although the effect was limited to clinical CR, intraperitoneal CDDP administration for metastatic ovarian cancer is effective for improving short-term prognosis.
 ...
PMID:[Intraperitoneal chemotherapy of metastatic ovarian cancer]. 153 Mar 46

The fluoropyrimidines fluorouracil (5-FU) and 5-fluoro-2'-deoxyuridine (FdUrd) have shown activity in a variety of malignancies. Nevertheless, even in initially responsive tumors, the development of resistance is a frequent problem. To understand the biochemical basis for acquired resistance, two pairs of cell lines were investigated. MCF7/Adr cells were obtained from the breast cancer cell line MCF7 by incubation with increasing concentrations of Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH). These cells are resistant to Adriamycin (200- to 600-fold) and cross-resistant to 5-FU (25-fold) and FdUrd (67-fold). The resistant cells showed significantly increased levels of thymidylate synthase, the target enzyme of the fluoropyrimidines' active metabolite, 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP). Other biochemical characteristics, including folate pools, drug uptake, metabolism, and retention, were unchanged. Fd9XR cells have been selected from a human colon cancer cell line (HCT-8) by exposure to FdUrd. These cells are resistant to FdUrd (1,000-fold) but not 5-FU. Biochemical evaluations show that the resistant cells are deficient of thymidine kinase and are thus unable to convert FdUrd to FdUMP. This understanding of the various biochemical mechanisms is essential for the design of specific modulations to overcome resistance to fluoropyrimidines.
 ...
PMID:Mechanisms of resistance to fluoropyrimidines. 153 73


1 2 3 4 5 6 7 8 9 10 Next >>